Cellanome IPO

Cellanome develops single-cell analysis technologies and platforms that enable researchers to study individual cells at unprecedented resolution and scale. The company's proprietary microfluidics and computational biology approaches allow scientists to analyze cellular heterogeneity, understand disease mechanisms, and identify therapeutic targets with greater precision than traditional bulk analysis methods. Cellanome's technology platform supports applications in cancer research, immunology, neuroscience, and drug discovery by providing detailed insights into cellular behavior and responses.

The company operates in the rapidly growing single-cell genomics market, which has become essential for advancing personalized medicine and understanding complex biological systems. Cellanome's solutions combine hardware, reagents, and software to provide researchers with integrated workflows for single-cell RNA sequencing, proteomics, and multi-omics analysis. The company serves pharmaceutical companies, biotechnology firms, and academic research institutions that require high-resolution cellular analysis capabilities for their research programs.